Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991

British Journal of Dermatology

Volumn 169, Issue 2, 2013, Pages 389-397

  Holterhues, C ^a,b   Hollestein, L M ^a   Nijsten, T ^a   Koomen, E R ^c   Nusselder, W ^a   De Vries, E ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Eindhoven Cancer Registry   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CUTANEOUS MELANOMA; DISABILITY; DISEASE DURATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; COST OF ILLNESS; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; MORTALITY, PREMATURE; NETHERLANDS; REGISTRIES; SEX DISTRIBUTION; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84881593685     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12346     Document Type: Article

References (36)

1. Netherlands Cancer Registry. Cijfers over kanker. Available at: http://cijfersoverkanker.nl (last accessed 1 May 2013).
2. de Vries E, Houterman S, Janssen-Heijnen ML, et al,. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol 2007; 18: 1110-16.
3. Kolmel KF, Kulle B, Lippold A, Seebacher C,. Survival probabilities and hazard functions of malignant melanoma in Germany 1972-1996, an analysis of 10 433 patients. Evolution of gender differences and malignancy. Eur J Cancer 2002; 38: 1388-94.
4. MacKie RM, Bray CA, Hole DJ, et al,. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-91.
5. Smith JA, Whatley PM, Redburn JC,. Improving survival of melanoma patients in Europe since 1978. EUROCARE Working Group. Eur J Cancer 1998; 34: 2197-203.
6. Hollestein LM, van den Akker SA, Nijsten T, et al,. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23: 524-30.
7. Cornish D, Holterhues C, van de Poll-Franse LV, et al,. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20 (Suppl. 6): vi51-8.
8. Holterhues C, van de Poll-Franse LV, de Vries E, et al,. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. J Eur Acad Dermatol Venereol 2012; 26: 1389-95.
9. Burnet NG, Jefferies SJ, Benson RJ, et al,. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005; 92: 241-5.
10. Guy GP, Ekwueme DU,. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011; 29: 863-74.
11. Salama AK, Rosa N, Scheri RP, et al,. The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. Cancer Invest 2012; 30: 637-41.
12. Brochez L, Myny K, Bleyen L, et al,. The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem. Melanoma Res 1999; 9: 614-18.
13. Ekwueme DU, Guy GP Jr, Li C, et al,. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011; 5 (Suppl. 1): S133-43.
14. Schouten LJ, Straatman H, Kiemeney LA, et al,. The capture-recapture method for estimation of cancer registry completeness: a useful tool? Int J Epidemiol 1994; 23: 1111-16.
15. van der Sanden GA, Coebergh JW, Schouten LJ, et al,. Cancer incidence in The Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer 1995; 31A: 1822-9.
16. Murray CJ, Lopez AD, Jamison DT,. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994; 72: 495-509.
17. Stouthard MEA, Essink-Bot M-L, Bonsel GJ, et al,. Disability Weights for Diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, 1997.
18. Mols F, Thong MS, Vissers P, et al,. Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 2012; 48: 2037-42.
19. Dutch Melanoma Guidelines. Available at: http://oncoline.nl/melanoom (last accessed 1 May 2013).
20. Eisemann N, Jansen L, Holleczek B, et al,. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol 2012; 167: 606-12.
21. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ,. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003; 1: 4.
22. World Health Organization. Gobal Burden of Disease 2004 update: disability weights for diseases and conditions. Available at: http://www.who.int/healthinfo/global-burden-disease/GBD2004-DisabilityWeights. pdf (last accessed 6 May 2013).
23. McInnes DK, Cleary PD, Stein KD, et al,. Perceptions of cancer-related information among cancer survivors: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer 2008; 113: 1471-9.
24. Davies NJ, Kinman G, Thomas RJ, Bailey T,. Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology 2008; 17: 1048-52.
25. Welch HG, Black WC,. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605-13.
26. Frangos JE, Duncan LM, Piris A, et al,. Increased diagnosis of thin superficial spreading melanomas: a 20-year study. J Am Acad Dermatol 2012; 67: 387-94.
27. Holterhues C, Cornish D, van de Poll-Franse LV, et al,. Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Arch Dermatol 2011; 147: 177-85.
28. Albert VA, Koh HK, Geller AC, et al,. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990; 23: 308-10.
29. Soerjomataram I, Lortet-Tieulent J, Ferlay J, et al,. Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer. BMC Med Res Methodol 2012; 12: 125.
30. Murray CJ, Lopez AD,. The Global Burden of Disease. Boston: Harvard School of Public Health, 1996.
31. Victorian burden of disease study. Mortality and morbidity in 2001. Available at: http://docs.health.vic.gov.au/docs/doc/ 6AEAFAB1BAE696B9CA257886000158A0/$FILE/bod-2001.pdf (last accessed 6 May 2013).
32. Rehm J, Frick U,. Valuation of health states in the U.S. study to establish disability weights: lessons from the literature. Int J Methods Psychiatr Res 2010; 19: 18-33.
33. Salomon JA, Vos T, Hogan DR, et al,. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-43.
34. Fields RC, Coit DG,. Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am 2011; 20: 181-200.
35. van der Leest RJ, Liu L, Coebergh JW, et al,. Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008. Br J Dermatol 2012; 167: 1321-30.
36. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al,. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840-50.